GNPX - Genprex' stock jumps after corporate update

Genprex shares rise ([[GNPX]] +6.5%) after the clinical-stage gene therapy company lists out its 2020 achievements and expected milestones for the year in a letter to its shareholders.The progress on the company's Acclaim-1 and Acclaim-2 trials evaluating REQORSA separately in combination with Tagrisso and Keytruda remain on track, and Genprex expects to initiate both trials in the first-half of 2021."The $40 million-plus in capital infusions in 2020 have provided us with a strong balance sheet as 2021 begins," CEO Rodney Varner said.

For further details see:

Genprex' stock jumps after corporate update